Share 'Promising News from Sarepta on Exon 51 Skipping Trial'
The much-anticipated 48-week results on eteplirsen, a drug designed to skip exon 51, were presented today by Sarepta Therapeutics on a webinar and press release. On the webinar, Sarepta’s Chief Executive Chris Garabedian presented data about the dystrophin found in study participants’ muscle biopsies and the 6-minute walk results.
To read some background about this clinical trial, click here.
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this